A modification of the standard intraperitoneal paclitaxel/cisplatin chemotherapy regimen results in higher completion rates

被引：0
|
作者：
Lesnock, J. [1 ]
Richard, S. D. [1 ]
McBee, W. C. [1 ]
Zom, K. K. [1 ]
Sukumvanich, P. [1 ]
Edwards, R. P. [1 ]
Krivak, T. C. [1 ]
机构：
[1] Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Magee Womens Hosp, Pittsburgh, PA USA
来源：
GYNECOLOGIC ONCOLOGY | 2009年 / 112卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
108
引用
收藏
页码：S55 / S55
页数：1
相关论文
共 50 条
  • [1] A new modification of the standard IV/IP paclitaxel/cisplatin chemotherapy regimen that results in higher completion rates
    Mcbee, W. C.
    Richard, S. D.
    Lesnock, J. L.
    Sukumvanich, P.
    Krivak, T. C.
    Zom, K. K.
    Kelley, J. L.
    Edwards, R. P.
    GYNECOLOGIC ONCOLOGY, 2008, 111 (02) : 373 - 374
  • [2] Impact of modification of the standard intraperitoneal paclitaxel/cisplatin chemotherapy regimen on progression-free survival
    Lesnock, J.
    Chu, T.
    Richard, S.
    Kubenik, M.
    Krivak, T.
    Zorn, K.
    Sukumvanich, P.
    Kelley, J.
    Edwards, R.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S136 - S136
  • [3] Does age affect completion rates for intraperitoneal chemotherapy?
    Richard, S. D.
    McBee, W. C.
    Lesnock, J.
    Sukumvanich, P.
    Zorn, K. K.
    Edwards, R. P.
    Krivak, T. C.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S124 - S125
  • [4] Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
    Loek A. W. de Jong
    Marie Lambert
    Nielka P. van Erp
    Lukas de Vries
    Etienne Chatelut
    Petronella B. Ottevanger
    Cancer Chemotherapy and Pharmacology, 2023, 91 : 247 - 256
  • [5] Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
    de Jong, Loek A. W.
    Lambert, Marie
    van Erp, Nielka P.
    de Vries, Lukas
    Chatelut, Etienne
    Ottevanger, Petronella B.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (03) : 247 - 256
  • [6] Toxicity of a modified outpatient regimen of intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in women with newly diagnosed ovarian cancer
    Ferguson, Sarah E.
    Black, Destin
    Chi, Dennis S.
    Sabbatini, Paul
    Konner, Jason
    Tew, William P.
    Hensley, Martee L.
    Barakat, Richard R.
    Aghajanian, Carol
    GYNECOLOGIC ONCOLOGY, 2007, 104 (03) : S17 - S18
  • [7] Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin is comparable to results from GOG 172
    Barlin, J.
    Dao, F.
    Zgheib, N. Bou
    Ferguson, S.
    Sabbatini, P.
    Hensley, M.
    Konner, J.
    Tew, W.
    Aghajanian, C.
    Chi, D.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S36 - S37
  • [8] A new standard antiemetic regimen for patients receiving cisplatin chemotherapy
    Nature Clinical Practice Oncology, 2006, 3 (9): : 467 - 468
  • [9] Intraperitoneal cisplatin therapy in ovarian cancer: Comparison with standard intravenous carboplatin and paclitaxel
    Ozols, Robert F.
    Bookman, Michael A.
    Young, Robert C.
    Du Bois, Andreas
    Pfisterer, Jacobus
    Reuss, Alexander
    GYNECOLOGIC ONCOLOGY, 2006, 103 (01) : 1 - 6
  • [10] Combination chemotherapy with paclitaxel and intraperitoneal cisplatin for ovarian cancer with disseminated lesions in the peritoneum and the diaphragm
    Terauchi F.
    Moritake T.
    Yamamoto Y.
    Ogura H.
    International Journal of Clinical Oncology, 2002, 7 (6) : 356 - 360
12345